Nasdaq Stockholm AB: Cell Impact AB (publ) receives observation status (542/23)

On October 23, 2023, Cell Impact AB (publ) (the "Company") disclosed a press
release with information that the Company intends to resolve on a rights issue.
The press release also stated that the Company had entered into bridge loan
agreements which would ensure sufficient liquidity during the period November
until December 2023. The payment of the bridge loan to the Company is among
other things conditional upon the board of directors resolving on the rights
issue after obtaining authorization from an extraordinary general meeting in
the Company. 

The rules of Nasdaq First North Growth Market state that an issuer can be given
observation status if there is material adverse uncertainty in respect of the
issuer's financial position. 

With reference to the above, Nasdaq Stockholm AB decides that the shares in
Cell Impact AB (publ) (CI, ISIN code SE0017885379, order book ID 92429) shall
be given observation status. 

For further information about this exchange notice please contact Enforcement &
Investigations, telephone [phone].